Collegium Pharmaceutical, Inc. is a pharmaceutical company, which engages in development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. The company is headquartered in Stoughton, Massachusetts and currently employs 207 full-time employees. The company went IPO on 2015-05-07. The firm commercializes its pain portfolio, consisting of Xtampza extended-release (ER), Nucynta Products, Belbuca, and Symproic in the United States. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. Xtampza ER is for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The Nucynta Products are extended-release (ER) and immediate-release (IR) formulations of tapentadol. Nucynta ER is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. Nucynta IR is indicated for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults. Belbuca is a buccal film that contains buprenorphine, a partial opioid agonist. Symproic is an oral formulation of naldemedine.